| Business Summary | | OraSure
Technologies,
Inc.
develops,
manufactures
and
markets
oral
fluid
specimen
collection
devices
using
its
proprietary
oral
fluid
technologies,
proprietary
diagnostic
products
including
in
vitro
diagnostic
tests,
and
other
medical
devices.
These
products
are
sold
in
the
United
States
and
certain
foreign
countries
to
public
and
private-sector
clients,
clinical
laboratories,
physician
offices,
and
hospitals,
and
for
workplace
testing.
OraSure
Technologies'
business
focuses
on
the
following
principal
platform
technologies:
the
OraSure
oral
fluid
collection
device;
the
OraQuick
rapid
diagnostics
test
device;
and
the
new
up-converting
phosphor
technology.
In
addition,
the
Company
sells
certain
other
products,
including
the
Histofreezer
cryosurgical
system,
certain
immunoassay
tests
and
reagents
for
insurance
risk
assessment
and
forensic
toxicology
applications,
an
oral
fluid
Western
Blot
confirmatory
test
for
HIV-1,
and
the
Q.E.D.
Saliva
Alcohol
Test. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | OraSure
Technologies,
Inc.
develops,
manufactures
and
markets
oral
specimen
collection
device,
oral
fluid
assays,
proprietary
diagnostic
products,
and
other
medical
devices
to
healthcare
sector
customers.
For
the
six
months
ended
6/30/01,
revenues
rose
15%
to
$15.9
million.
Net
loss
rose
23%
to
$1.4
million.
Results
reflect
continued
penetration
in
the
public
health
market
and
new
product
introductions,
offset
by
staff
additions
and
a
$450
thousand
restructuring
charge. | More
from
Market Guide: Significant
Developments |
| | | Robert
D. Thompson,
CEO Michael
J. Gausling,
Pres./COO Sam
Niedbala,
Exec. VP William
D. Block,
Sr. VP Richard
D. Hooper,
VP-Fin./CFO. | More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|